SiRNA Manufacturing Model bakeng sa Tlhahiso ea Peptide

Seo mofuta oa tlhahiso ea siRNA bakeng sa tlhahiso ea peptide o ka se alimang ebile o ke ke oa alima

Haeba lenaneo la hau la peptide le se le fihlile moo ho eketsehang le moroalo oa litšila o seng o le sieo, mohlala oa tlhahiso ea siRNA bakeng sa tlhahiso ea peptide o lokela ho bala ka hloko, le molemo oa ho bala ka ho belaela. Patlisiso e senotsoeng ea Bachem ea "fragment-and-ligation" e hlalosa ho aha likhechana tse khutšoane tsa RNA le ho li kopanya ka mokhoa oa enzymatic ho fapana le ho kopanya ketane e le 'ngoe e telele., ka mabaka a moruo a boletsoeng a mehato e fokolang le e bonolo ea tlhoekiso, tšebeliso e tlase ea solvent, litšila tse fokolang le theko e tlaase ea thepa ka tekanyo ea gram ho ea ho multi-kilogram (Bachem, kgutlisitsoe 2026-09-21).

Fragment-and-ligation e bolela ho kopanya likotoana tse hlalositsoeng ka thoko ebe lia li kopanya, sebakeng sa ho hodisa ketane e le nngwe e sa kgaotseng. N-1 e khutsufalitsoeng ke ketane e hlokang masala a le mong, le racemization ke tahlehelo ea tlhophiso e reriloeng ea setsi sa chiral, both of which become harder to control as chains lengthen. Fit-for-purpose analytics means testing matched to what a decision needs, not to a fixed panel.

This is an interpretation of public material, not a peptide recipe. Nucleic-acid manufacturing versus peptide chemistry involves different coupling, protecting-group and stereochemistry problems, so the transferable part is process design, not chemistry.

What Bachem’s disclosed siRNA route actually describes

Bachem’s disclosed fragment-and-ligation case study, run with Codexis and using vutrisiran as the model siRNA, describes building the molecule from short RNA fragments that are synthesized separately and then joined enzymatically. The company reports that this route can “achieve high ligation efficiencies, simplify purification, le ho tšehetsa tlhahiso ea GMP ea lik'hilograma tse ngata,” e nang le boleng ba sehlahisoa e hlalosa hore e ka bapisoa le motsoako o tloaelehileng (Thuto ea mohlala ea Bachem, kgutlisitsoe 2026-09-21).

Moralo oa Bachem oa enzymatic ligation o fana ka mabaka a moruo: ho kopanya likaroloana tse khutšoane ho e-na le ho haha ​​ketane e le 'ngoe e telele ho fana ka "kotulo e phahameng le ho fokotsa meroalo ea tlhoekiso,” haholo-holo ka bongata (Setsi sa tsebo sa Bachem, kgutlisitsoe 2026-03-24).

Meeli e 'meli ea bohlokoa. Ena ke tlaleho ea morekisi ea ikemetseng: maqephe a bolela hore ha ho tlhahiso, bohloeki kapa lipalo tsa litšenyehelo, kahoo likopo tse sebetsang hantle le tsa theko ea thepa li ke ke tsa hlahlojoa khahlano le linomoro tse hatisitsoeng. 'Me phatlalatso e lutse ka har'a boemo bo pharaletseng, kaha leqephe la tlhahiso la oligonucleotide la Bachem le e hlahisa e le molekane ho li-peptide le oligonucleotide, e nang le sebaka se inehetseng sa GMP oligonucleotide le lihlopha tsa pele tsa GMP nakong ea likhoeli tse robong tsa ho raha. (Bachem oligonucleotide NCE leqephe, kgutlisitsoe 2026-07-30).

Moo papiso e robehang teng

Lintlha tse peli tsa tlhahiso li fapana ho k'hemistri ka boeona. Li-oligonucleotide li hahiloe nucleotide ka nucleotide ho tloha 5'-DMT-protected nucleoside-3'-phosphoramidites, ho palama baesekele ka ho putlama, Kopanya, oxidation kapa sulfurization, le capping. Li-peptide li hahiloe amino acid ka amino acid ka Fmoc kapa Boc solid-phase synthesis, ka tshireletso e pheta-phetoang le ho kopanngoa. Papiso ea k'hemistri ka lehlakore ka RSC Green Chemistry's 2023 tlhahlobo hlokomela litsela tse peli ha li tsamaellane ka kotloloho ntle le moralo o khethehileng oa sehlopha se sireletsang.

Litekanyetso tsa ho se hloeke li fapane haholo. Monahano oa tlhahlobo oa oligonucleotide oa FDA e hlalosa litšila tsa oligonucleotide e le mefuta e bolelele ba ketane (shortmers, nako e telele, n-1) le mefuta e fapaneng ea phosphorus-stereochemistry joalo ka phosphorothioate diastereomers, e nang le mefuta e bolelele bo felletseng le e haufi le bolelele bo felletseng boo chromatography e sa e tloseng. Tataiso ea EMA mabapi le li-peptide tsa maiketsetso ho fapana le moo e shebana le ho hlakolwa, truncations, racemization, fedile- le ho kopanya ka tlase, dimers le aggregates, le li-reagents tse setseng, solvents le counterions.

Li-peptide li boetse li na le litsi tsa chiral tse sieo mokokotlong oa nucleotide, mme pokeletso e itshetlehile ka tatelano ho fapana le ho lepa pele. Joalo ka peptide.com's SPPS ea karabelo ea lehlakore oa hlalosa, resin aggregation e baka tšireletseho e sa phethahalang le ho kopanya, sesupo sa ho hloleha ha resin ho ruruha, mme e ke ke ya bolela esale pele ka botshepehi ho tswa ho tatelano, le hoja tatellano ea hydrophobic e tloaelehile haholoanyane 'me ho ke ke ha etsahala hore ebe pele ho sala 5-6 kapa ka mora ho sala 21.

Melao-motheo e mene e fetisang

Lintho tse 'ne li fetela ho tlhahiso ea oligonucleotide: moralo oa mokhoa oa modular bakeng sa motsoako oa peptide, taolo ea litšila boemong ba mochini, meralo ya maemo a phahameng, le li-analytics tse loketseng morero bakeng sa tlhahiso ea peptide. E 'ngoe le e 'ngoe ke molao-motheo, eseng protocol e kopilitsoeng. Mokhahlelo o tiileng oa Organic Synthesis

Moralo oa mokhoa oa modular. Lebokose le fumanehang la lithulusi tsa moaho le se le na le li-amino acid tse sirelelitsoeng tse tloaelehileng, pseudoprolines le Dmb kapa isoacyl dipeptides, haufi le resin ea ka boomo le khetho ea linker (Merck/Novabiochem). Limela tse thehiloeng ho li-module li sebelisa li-blocks tse tšoanelehang hape ho eketsa bokhoni bo nang le kotsi e tlase ea thuto.

Taolo ea litšila mochining. Laola se hlahisang litšila, eseng tlhoro ea chromatogram. Referense ea karabelo ea lehlakore ea SPPS e thathamisa likhaello tse fetisoang joalo ka melao-motheo: Tšireletso ea DBU, NMP kapa DMSO cosolvent, mocheso o phahameng oa ho kopanya, le lintho tse senyang hydrogen-bond tse kang pseudoprolines le Hmb kapa Dmb tšireletso ea mokokotlo (peptide.com, 2019-10-14).

Thero ea maemo a holimo. Netefatsa mokhoa oa tsela, mokgoa wa ditshila, le ts'ebetso e tlase ka tekanyo e nyane pele o itlama ho lisebelisoa tse kholoanyane. Kamano ea exponential chaie-decay e hlalosa lebaka: ho 99% ho kopanya hantle, chai e felletseng e oela ho hoo e ka bang 82% kamora 20 likopano, 67% kamora 40, le 45% kamora 80 (Peptides Codex, 2026-09-14).

Litlhahlobo tse loketseng morero. Ke Q2(R2) litebello tsa netefatso li akaretsa tse ikhethang le khethollo, nepahalo, nepahalo, linearity le mefuta, robustness, le moeli oa palo ho kapa ka tlase ho moeli oa tlaleho; moo ditshila tsa nnete di seng teng, ho ka 'na ha bontšoa ka mokhoa oa bobeli oa orthogonal oa bobeli o tsejoang hantle (Ke Q2(R2), 2023-11-30, ho lokisa phoso 2025).

Sena se bolela eng ho baetsi ba peptide, Khetho ea CDMO le linako tsa mananeo

Bakeng sa baetsi ba peptide, melao-motheo e mene e fetola ntho e le 'ngoe ka holim'a tsohle: taolo ea litšila tsa peptide le moralo oa ho eketsa e ba bothata ba leano la taolo ho fapana le bothata ba tlhoekiso. Litebello tsa leano la taolo ea ICH Q11 hloka saense- le leano le thehiloeng ho kotsi le lokafatsang litlhaloso tsa thepa ea ho qala, e laola ditshila tsa ho qala, mme e bonts'a ts'ebetso ea ho ikatisa khahlano le litšoaneleho tsa boleng tse boletsoeng esale pele. E sebelisoa tseleng ea peptide, seo se bolela hore mekhoa ea ho se hloeke e lateloa ho tloha ka tiiso ea litsela ho ea pele, ha e fumanoe litekong tsa tokollo.

Bakeng sa khetho ea CDMO, mabaka a tšoanang a fetoha lipotso ho e-na le lipolelo. Kopa mokhethoa ho hlalosa sebopeho sa tumellano ea phepelo eo a e sebelisang: netefatso ea tekheniki e nyane pele, litšila mokhoa ya data bobeli, tshebetso e tlase ya boraro, khoebo Peptide Synthesis sekala qetellong. Liphatlalatso tsa boikoetliso ba CDMO, ho kenyelletsa tlaleho ea leano la Polypeptide Group le 2026 DCAT CDMO tlhahlobo, hlalosa mokhoa ona o hlophisitsoeng e le mokhoa oa litumellano tsa nako e telele, ke ka lebaka leo e sebetsang e le lense ea tlhahlobo ho e-na le tšepiso ea morekisi.

Linako li latela sethaleng seo. Lenaneo le netefatsang tsela le li-analytics pele le itlama ho ea khoebong le nka litšenyehelo tse ngata pele ho nako le ho se sebetse hape hamorao; e tlolang netefatso e hatella ntlha e ka pele mme e lefa ka tekanyo e phahameng. Ka li-peptides

Bakeng sa Keletso: Kopa leano la netefatso le behiloeng sethaleng pele u saena. Liphetoho tsa MOL li tšehetsa mofuta ona oa moralo o jarollotsoeng ka pele ka nts'etsopele ea ts'ebetso le lits'ebeletso tsa ho eketsa, ho tloha ho milligrams ho isa ho lik'hilograma.

Mehato e latelang

If the transferability question is now the live one for your program, the useful next step is a technical feasibility assessment rather than a commercial conversation. Ask for documentation covering three things: route-confirmation data for the sequence you actually intend to scale, impurity-profile reporting that shows how the profile is tracked across batches rather than reported as a single release number, and the release-testing documentation behind the analytical methods. Those three items let your CMC team judge fit before any supply commitment is discussed.

Liphetoho tsa MOL li fana ka motsoako oa peptide o tloaelehileng, process development and quality control for programs moving from milligrams to kilograms, and can supply that documentation package on request.

Lipotso Tse Botsoang Khafetsa

Na k'hemistri ea fragment-and-ligation e hlile e sebetsa ho li-peptide?

Karolo e 'ngoe, and the distinction matters. Native chemical ligation le mefuta e fapaneng ea eona e ile ea ntlafatsoa bakeng sa k'hemistri ea peptide pele oligonucleotide synthesis e alima mohopolo., kahoo mohopolo oa motheo ha o osele ho li-peptide ho hang. Seo se sa feteleng ke tekanyo ea tlhōlo. Papiso ea k'hemistri e lehlakoreng le leng e bonts'a hore kopano ea oligonucleotide e rua molemo haholo ho tloha ho fetohela ho tsela e tloaelehileng ho feta kopano ea peptide., hobane likhokahano tsa peptide li se li ntse li sebetsa ka katleho e phahameng ho tšehetso e tiileng. Tšoara ligation e le sesebelisoa se lebisitsoeng bakeng sa tatellano e hananang le motsoako oa stepwise, eseng joalo ka sethala se nkelang sebaka.

Re se re ikemiselitse ho sebelisa tsela e tloaelehileng ea SPPS. Ke eng e fetohang?

Ha ho letho ka k'hemistri, le tse ngata mabapi le moralo. Lebokose le fumanehang la lithulusi tsa li-peptide le se le pharaletse, kahoo mohato o sebetsang ke ho boloka SPPS le ho sebelisa monahano oa modular mabapi le hore na u nts'etsapele joang: confirm the route early, track impurity trends as a distinct workstream, and defer scale commitment until the trend is stable. Programs that treat impurity control as a late-stage cleanup problem rather than a running measurement tend to discover the hard numbers at the worst possible time.

Mosebetsi oa li-analytics o bohlokoa hakae?

More than most early programs budget for, and less than a fully validated commercial panel. Ke Q2(R2) validation expectations give you the framework: decide which methods are stability-indicating and which are merely in-process checks, then validate each to the standard its decision actually requires. Running a full release panel on every in-process sample is overengineering. Running nothing until the first scale batch is the opposite mistake.

The transferable elements are staged route confirmation, ho latedisa ditshila le diqeto tse hlalositsweng tsa tshekatsheko. Ho lokisoa ha sekhechana sa RNA le ho kopanya ha enzymatic ho kenyelletsa likaroloana tse fapaneng, litlhoko tsa enzyme le mekhoa ea litšila e tsoang ho peptide synthesis. Bontša tsela e ikhethileng ea peptide pele u alima ts'ebetso e sebetsang hantle kapa likopo tsa ho eketsa.

Qetello

Boleng ba mohlala oa siRNA ho tlhahiso ea peptide ke ea meralo, eseng lik'hemik'hale. Se fetisang ke taeo ea ho tiisa tsela ka mekhahlelo, ho laola litšila boemong ba mochine, le li-analytics tse tsamaellanang le qeto eo ba e tsebisang. Ntho e sa fetisetsoang ke chemistry ea synthesis ka boeona, le moralo ofe kapa ofe o sebetsanang le tsebo ea ts'ebetso ea oligonucleotide e le e nkehang habonolo e tla arola boiteko bo fosahetseng.

Haeba netefatso e hlophisitsoeng le taolo ea litšila tsa boemo ba mochini li fetoha tloaelo e tloaelehileng mananeong a peptide, liphello tse sebetsang li hlaha libakeng tse tharo. Bahlahisi ba emisa ho fumana ka morao ho nako hore tsela e ke ke ea boloka boemo ba eona ba litšila ka bongata. Khetho ea CDMO e fetoha ho tloha ho bapisa linomoro tsa bohloeki ba lihlooho ho ea ho bapisa kamoo mofani oa thepa a netefatsang tsela pele a e etsa.. Mananeo a nako a lenaneo a nka litšenyehelo tse ngata pele ho nako mme a fokotsehe ho sebetsa hape hamorao, e leng khoebo e betere bakeng sa peptide efe kapa efe e lebang phepelong ea khoebo.

Mohato o latelang ha se qeto ea theknoloji. Ke sebaka sa scoping: pele ho letšolo le latelang la ho phahamisa, ngola hore na ke litšila life tseo tsela ea hao ea hona joale e ka li laolang le tseo u ke keng ua li laola, le hore na u tla tseba ka nako efe ts'ebetsong. Lenane leo ke lona le etsang hore puisano ea bokhoni ba tekheniki e be molemo, hore na u na le eona ka hare kapa le molekane oa tlhahiso.